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Comparison of 18F-Fluoro-L-DOPA, 18F-Fluoro-
Deoxyglucose, and 18F-Fluorodopamine PET and
123I-MIBG Scintigraphy in the Localization of
Pheochromocytoma and Paraganglioma
Henri J. L. M. Timmers, Clara C. Chen, Jorge A. Carrasquillo, Millie Whatley,
Alexander Ling, Bastiaan Havekes, Graeme Eisenhofer, Lucia Martiniova,
Karen T. Adams, and Karel Pacak*
Context: Besides 123I-metaiodobenzylguanidine (MIBG), positron emission tomography (PET)
agents are available for the localization of paraganglioma (PGL), including 18F-3,4-dihydroxy-
phenylalanine (DOPA), 18F-fluoro-2-deoxy-D-glucose (18F-FDG), and 18F-fluorodopamine
(18F-FDA).
Objective: The objective of the study was to establish the optimal approach to the functional
imaging of PGL and examine the link between genotype-specific tumor biology and imaging.
Design: This was a prospective observational study.
Intervention: There were no interventions.
Patients: Fifty-two patients (28males, 24 females, aged 46.8 14.2 yr): 20with nonmetastatic PGL
(11 adrenal), 28 with metastatic PGL (13 adrenal), and four in whom PGL was ruled out; 22 PGLs
were of the succinate dehydrogenase subunit B (SDHB) genotype.
Main Outcome Measures: Sensitivity of 18F-DOPA, 18F-FDG, and 18F-FDA PET, 123I-MIBG scintigra-
phy, computed tomography (CT), and magnetic resonance imaging (MRI) for the localization of
PGL were measured.
Results: Sensitivities for localizing nonmetastatic PGL were 100% for CT and/or MRI, 81% for
18F-DOPA PET, 88% for 18F-FDG PET/CT, 78% for 18F-FDA PET/CT, and 78% for 123I-MIBG scin-
tigraphy. Formetastatic PGL, sensitivity in reference to CT/MRI was 45% for 18F-DOPA PET, 74%
for 18F-FDG PET/CT, 76% for 18F-FDA PET/CT, and 57% for 123I-MIBG scintigraphy. In patients
with SDHB metastatic PGL, 18F-FDA and 18F-FDG have a higher sensitivity (82 and 83%) than
123I-MIBG (57%) and 18F-DOPA (20%).
Conclusions: 18F-FDA PET/CT is the preferred technique for the localization of the primary PGL and
to rule out metastases. Second best, equal alternatives are 18F-DOPA PET and 123I-MIBG scintig-
raphy. For patients with known metastatic PGL, we recommend 18F-FDA PET in patients with an
unknown genotype, 18F-FDG or 18F-FDA PET in SDHBmutation carriers, and 18F-DOPA or 18F-FDA
PET in non-SDHB patients. (J Clin Endocrinol Metab 94: 4757–4767, 2009)
Paragangliomas (PGLs) derive from sympathetic chro-maffin tissue in adrenal and extraadrenal abdominal or
thoracic locationsor fromparasympathetic tissueof thehead
and neck (1). The terms pheochromocytoma and glomus
tumor refer to respective adrenal PGL and head and neck
PGL (2, 3). The majority of abdominal and thoracic PGLs
produce catecholamines (4), whereas head and neck PGLs
usually do not. This study focused on sympathetic PGL.
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Accurate tumor localization is critical for guiding the
optimal therapeutic approach for PGL, in particular for
identification of multiple primary tumors or metastases.
Lesions detected by anatomical imaging can be specif-
ically identified as PGL by functional imaging agents
that target the catecholamine synthesis, storage, and
secretion pathways of chromaffin tumor cells (5). These
techniques include [123/131I]metaiodobenzylguanidine
(MIBG) scintigraphy, 6-[18F]fluoro-L-3,4-dihydroxy-
phenylalanine (DOPA) positron emission tomography
(PET), and6-[18F]fluorodopamine (FDA)PET.2-[18F]fluoro-
2-deoxy-D-glucose (FDG) PET provides another modal-
ity for localization of metastatic PGL, albeit with less
tissue specificity than the other functional approaches
that target the catecholamine biosynthetic and storage
pathways (6–8).
Previous studies on the performance of different
functional imaging modalities in PGL yielded discrep-
ant results (8–15). Meaningful comparisons among
these studies is hampered by heterogeneous patient
sample groups with respect to PGL location (adrenal
and extraadrenal abdominal vs. thoracic vs. head and
neck), benign vs. malignant PGL, and hereditary vs.
sporadic PGL. At least 25–30% of patients with PGL
have underlying mutations in one of the four known
PGL susceptibility genes (16). The various PGL geno-
types are increasingly recognized as important determi-
nants of functional imaging results. For example, 18F-
FDA PET is superior to 123I-MIBG scintigraphy in the
context of von Hippel Lindau (VHL) syndrome (17),
whereas 18F-FDG PET is extremely sensitive in meta-
static PGL associated with mutations in succinate de-
hydrogenase subunit B (SDHB) (8).
Individually, the PET tracers 18F-FDA, 18F-DOPA, and
18F-FDG have been claimed to be superior to 123I-MIBG
for the localization of PGL in the particular clinical con-
texts of different studies. So far, however, a comprehen-
sive comparison between these tracers within the same
patient population has not been performed. In the present
study, such a head-to-head comparisonwas accomplished
in a large, heterogeneous group of patients with benign
and malignant PGLs of various locations and genotypes.
The aim of this study was to establish the optimal ap-
proach to the functional imaging of sympathetic PGL and
further explore possible links between tumor genotypes
and imaging.
Patients and Methods
Patients
Between June 2006 and June 2008, we prospectively studied
53 patients (29 males, 24 females, mean SD, aged 46.8 14.2
yr), who were consecutively evaluated for known or suspected
PGL. At the time of the study, 20 patients had histologically
proven, nonmetastatic PGL (no. p1-20), including 11 with ad-
renal PGL, seven with extraadrenal abdominal or thoracic PGL,
one with bilateral adrenal and an extraadrenal PGL, and one
with a catecholamine secreting head PGL. Twenty-eight patients
had metastatic PGL (no. m1-28), including 13 with primary ad-
renal tumors and 15 with primary extraadrenal abdominal or
thoracic tumors. Metastatic PGL was defined by the presence of
metastatic lesions at sites in which chromaffin tissue is normally
absent (18). In four patients, PGL was ruled out by normal bio-
chemical findings (no. n1-4). One patient was excluded from the
analysis because a histological diagnosis was still pending. Clin-
ical details of individual patients, including previous treatments,
are listed in Tables 1–3.
Twenty-two patients had an underlying mutation of the
SDHB gene, four of the succinate dehydrogenase subunit D
(SDHD) gene, three of the rearranged during transfection pro-
tooncogene, and two of theVHL gene. Six patients had sporadic
tumors, two were not tested, and in 14 patients lacking syn-
dromic features, at least SDHx mutations were ruled out. The
results of 18F-DOPA PET scanning in the first 11 patients were
reported in a previous paper on the usefulness of the adminis-
tration of carbidopa before scanning (19).
This protocol was approved by the Institutional Review
Board of the National Institute of Child Health and Develop-
ment at the National Institutes of Health. All patients provided
written informed consent.
Computed tomography (CT) and magnetic
resonance imaging (MRI)
In all 53 patients, CT scans of the neck, chest, abdomen, and
pelvis were performed, using LightSpeedUltra, LightSpeedQX/i
(General ElectricHealthcare Technologies,Waukesha,WI), and
Mx8000 IDT (PhilipsMedical Systems,Andover,MA) scanners.
Section thickness was 2–2.5 mm in the neck and 5 mm through
the chest, abdomen, and pelvis. Studies were performed with a
rapid infusionof nonionicwater-soluble contrast agent aswell as
oral contrast material.
In 45 patients, additional MRI scans of the neck, chest, ab-
domen, and/or pelvis were obtained, using 1.5 or 3 Tesla scan-
ners (General ElectricHealthcareTechnologies andPhilipsMed-
ical Systems). Phased-array coils were used for neck imaging and
either phased array torso or quadrature body coils elsewhere.
T1-weighted gradient-echo, and short- inversion recovery
and/or fat-suppressed fast spin-echo T2-weighted imaging pa-
rameters were adjusted to minimize examination time but
achieving desired anatomic coverage. Image thicknesswas 5mm
for neck studies and5–8mmfor other body regions. Preinjection
images were obtained in the axial plane. Studies included injec-
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tion of a gadolinium-111In-diethylenetriamine-pentacetic acid
contrast agent, using fat-suppressed T1-weighted gradient-echo
imaging, generally in both axial and coronal planes.
Functional imaging
123I-MIBG scintigraphy, 18F-FDG PET/CT, 18F-DOPA PET,
and 18F-FDA PET/CT were performed as described previously
(8, 19). 18F-DOPA PET scanning was preceded by oral admin-
istration of 200mg carbidopa, a peripheral aromatic amino acid
decarboxylase inhibitor (19). All patients underwent 18F-DOPA
PETand18F-FDAPET/CT, all but oneunderwent 18F-FDGPET/
CT, and all but three underwent 123I-MIBG scintigraphy.
Analysis of data
CT andMRI scans were read by a single radiologist who was
blinded to results of other imaging studies. Lesions detected by
CT and/or MRI that were typical or highly suspicious for PGL
were considered positive.
18F-DOPA PET and 18F-FDA PET were each read in blinded
fashion by two nuclear medicine physicians during separate
reading sessions. Focal areas of abnormal uptake not corre-
sponding to normal physiological sites of accumulation for each
of the tracer were considered as lesions. Lesions were graded on
a scale of 1–5 (1, not PGL; 2, doubtful; 3, equivocal; 4, probable;
5, definite PGL). Lesions with scores of 4 and 5 were counted as
positive findings. Discrepancies were resolved by consensus
review.
Lesions detected byCT,MRI, and functional imaging studies
were counted in the following three separate body regions: neck,
thorax, and abdomen/pelvis. Counts included both soft tissue
andbone lesions. If thenumberof lesions ina regionexceeded10,
the count was truncated at 10 to avoid bias toward that patient.
Lesions of the head and extremities were not included in the
analysis because these areaswerenot systematically scanned. For
this reason, primary nonsecreting head and neck paraganglio-
mas were excluded from the analysis.
Imaging results in individual patients were compared be-
tween scans performed within a 3-month interval, with the ex-
ception of one patient (no. m4), in whom 18F-FDG PET was
performed with a delay of 7 months. In this interval, he did not
undergo treatment, and repeat CT showed no additional lesions.
Sensitivities for tumor detection were calculated in reference
to two different gold standards. In patients with nonmetastatic
PGL, sensitivities were calculated in reference to histopatholog-
ically confirmedPGLs. If surgical resectionof the culprit lesion(s)
resulted in normalization of plasma-free metanephrines without
signs of recurrence during follow-up, additional lesions of the
chest and abdomen on preoperative imaging were presumed to
be false positive. In patientswithmetastatic PGL, comprehensive
histopathological confirmation of all lesions to serve as gold
standard for imaging results was not feasible. Instead, the sen-
sitivity for metastases was calculated in reference to lesions de-
tected by CT and/or MRI. The sensitivity for metastases was
based on per-region counts as stated above, not on a per-lesion
basis.
Sensitivities were analyzed separately in patients with non-
metastatic and metastatic disease. Prompted by earlier findings
in patients with SDHB-related PGL (8), sensitivities for the de-
tection of metastases were compared between patients with and
without underlying SDHB mutations.TA
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Statistics
Results are given as mean  SD unless stated otherwise. The
McNemar test was used to compare sensitivities between differ-
ent functional imagingmodalities. A 2 testwas used to compare
sensitivities between patients with and without SDHB muta-
tions. A two-sided P  0.05 was considered significant. Statis-
tical analysis was performed using Statistical Package for the
Social Sciences (SPSS for Windows 12; SPSS Inc., Chicago, IL).
Results
Nonmetastatic PGL
In 20 patients, 26 nonmetastatic PGLs were his-
topathologically identified. Besides anatomic imaging, all
types of functional imagingwere performed in all patients.
One patient (no. p1) had inadvertently taken 40 mg in-
stead of 200 mg carbidopa before 18F-DOPA PET. Dis-
crepant readings were solved by consensus for two lesions
on 18F-DOPA PET.
Of 26 PGLs, all lesions were detected by CT and/or
MRI (sensitivity 100%), 21 by 18F-DOPAPET (sensitivity
81%), 20 by 18F-FDA PET/CT (sensitivity 78%), 20 by
123I-MIBG scintigraphy (sensitivity 78%), and 23 by 18F-
FDGPET/CT (sensitivity 88%,P ns, Table 4). Six false-
positive lesions were detected. 123I-MIBG scintigraphy
showed two false-positive chest lesions in one patient (no.
p12). 18F-FDG PET/CT showed three false-positive le-
sions. In one patient (no. p13), a right inguinal lesion on
18F-FDG PET/CT [maximum standardized uptake value
(suv) 4.5] correlated with a 1.9 cm normal-appearing
lymph node on CT. In another patient (no. 16), the 18F-
FDG PET/CT showed two small foci in the vertebral bod-
ies of T9 (maximum suv 2.6) and L5 (maximum suv 4.2),
not correlating with abnormalities on anatomical imag-
ing. Clinical follow-up of 1.5 yr showed no (biochemical)
evidence of recurrent or metastatic disease in either of
these patients. 18F-FDA PET/CT showed one false-posi-
tive lesion (no. 16). Therewere no false-positive lesions on
CT, MRI, and 18F-DOPA PET.
Metastatic PGL
All 28 patients with metastatic PGL underwent ana-
tomical imaging and all types of functional imaging, ex-
cept for three patients who did not undergo 123I-MIBG
scintigraphy, and one patient who did not undergo 18F-
FDG PET. In reference to CT and/or MRI region-based
sensitivities were: 18F-FDA PET/CT, 76% (161 of 211);
18F-FDG PET/CT, 74% (157 of 211); 123I-MIBG scintig-
raphy, 57% (106 of 187); and 18F-DOPA PET, 45% (96
of 211). These results were significantly different between
the imaging techniques (P  0.01), except between 18F-
FDA and 18F-FDG (P  ns, Table 4 and Fig. 1).
In one patient (no. m23), no lesions were detected by
any imaging study, who previously underwent metasta-
sectomy. In the remaining patients, one or more lesions
were detected by CT and/or MRI in 24 of 27 patients
(89%), 18F-FDG PET/CT in 24 of 27 patients (89%), 18F-
FDA PET/CT in 22 of 27 patients (81%), 18F-DOPA PET
in 20 of 27 patients (74%), and 123I-MIBG scintigraphy in
21 of 25 patients (84%).
In the 28 patients, a total score of 334 lesions was ob-
tained from all anatomic and functional imaging studies
by regional analysis. The total score for 18F-FDA PET/CT
alone was 246, 211 for CT and/or MRI, 174 for 18F-
DOPAPET, and 209 for 18F-FDGPET/CT. Lesion counts
were truncated at 10 in 16 regions for 18F-FDA PET/CT,
10 regions for CT and/or MRI, 10 regions for 18F-FDG
PET/CT, and nine regions for 18F-DOPA PET. In the 25
patients who underwent 123I-MIBG scintigraphy, 122 le-
sions were counted and were truncated in three regions.
Functional imaging sensitivities for metastatic lesions
were compared between 15 patients with and 13 patients
without mutations of the SDHB gene. In SDHB patients,
18F-FDG PET/CT detected metastases in all patients,
whereas several other scans were false negative: in three
patients (no. m13, m15, m28), no lesions were visualized
by 18F-FDA, 18F-DOPA, or 123I-MIBG, in another (no.
m7), no lesionswere detected by 18F-FDAand 18F-DOPA,
TABLE 4. Sensitivity
CT and/or
MRI 18F-DOPA 18F-FDA 123I-MIBG 18F-FDG
Nonmetastatic PGL (20 patients)
In reference to histologically confirmed
lesions
100% (26/26) 81% (21/26) 77% (20/26) 77% (20/26) 88% (23/26)
Sensitivities are not significantly different between functional imaging modalities
CT and/or
MRI 18F-DOPAA 18F-FDAB 123I-MIBGC 18F-FDGD
Metastatic PGL (28 patients)
In reference to lesions on CT and/or MRI 45% (96/211) 76% (161/211) 57% (106/187) 74% (157/211)
A vs. B, A vs. C, A vs. D, B vs. C, C vs. D: P  0.01; B vs. D: P  0.760.
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and in three (no. m20, 21, and m27) 18F-DOPA was false
negative (123I-MIBG not done in no. m27). In non-SDHB
patients, a false-negative 18F-FDG scan was obtained in
one patient (no. m12 with VHLmutation), and 18F-FDA
was negative in one patient (no. m10, sporadic). Using
CT/MRI as a gold standard, lesion-based sensitivities in
SDHB vs. non-SDHB patients are given in Table 5. In
SDHB patients, 18F-FDA and 18F-FDG have a higher sen-
sitivity (82 and 83%) than 123I-MIBG (57%) and 18F-
DOPA (20%). In non-SDHB patients, 18F-DOPA has the
best sensitivity (93%), followed by 18F-FDA (76%), 123I-
MIBG (59%), and 18F-FDG (62%).
PGL ruled out
In the four patients in whom PGL was ruled out by
biochemical investigation and clinical follow-up, two had
FIG. 1. Functional imaging in patients no. m4 with metastatic SDHB PGL (panel 1), m15 with metastatic SDHB PGL (panel 2), and m6 with
metastatic RET PGL (panel 3). Anteriorly reprojected images.
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false-positive lesions on imaging. One patient (no. n03), a
carrier of an SDHBmutation (IVS1 1GT), was found
to have an 8-  5-cm gastrointestinal stromal tumor be-
tween the stomach and pancreas, which was visualized by
CT,MRI, 18F-DOPAPET, and 18F-FDGPET/CTbut neg-
ative on 18F-FDAPET/CTand 123I-MIBG scintigraphy. In
the second patient (no. n01), a 2-cm left adrenal inciden-
taloma was seen on CT and MRI, which was also visible
on 18F-FDG PET/CT.
Discussion
Wepresent the first comprehensive head-to-head compar-
ison between 18F-FDA and 18F-FDG PET/CT, 18F-DOPA
PET, and 123I-MIBG scintigraphy for localizing benign
and malignant sympathetic PGLs. Nonmetastatic PGLs
were equally well localized by these techniques. For the
detection of metastases seen on CT, however, 18F-FDA
was superior to 18F-DOPA and 123I-MIBG scanning.
SDHB-related metastatic disease is best detected by 18F-
FDG PET/CT, whereas 18F-DOPA PET performs best in
non-SDHB patients.
Different functional imaging agents target PGL tumor
cells through different mechanisms. 123I- and 131I-labeled
MIBG and 18F-FDA are actively transported into neuro-
secretory granules of catecholamine-producing cells via
the vesicular monoamine transporters after uptake into
cells by the norepinephrine transporter (20). In contrast,
18F-DOPA enters the cell via the amino acid transporter
based on the capability of PGL and other neuroendocrine
tumors to take up, decarboxylate, and store amino acids
and their biogenic amines (20, 21). Instead of targeting
catecholamine pathways, 18F-FDG enters the cell via the
glucose transporter, and its accumulation is an index of
increased glucose metabolism (22, 23).
Abiochemical diagnosis of PGL is typically followedby
anatomic and functional imaging studies to localize the
primary tumor(s) and rule outmetastases. 123I/131I-MIBG
is the most widely used tracer in the first-line functional
imaging of PGL. 123I-MIBG is preferred over 131I-MIBG
because of its higher sensitivity, lower radiation exposure,
and improved imaging quality with single-photon emis-
sion-computed tomography (24). Previous studies suggest
a sensitivity of 123I-MIBG scintigraphy of 92–98% for
nonmetastatic PGL (15) and 57–79% for metastases (8,
15). The present findings confirm that the sensitivity is
high for primary tumors and relatively poor (50%) for
metastases.We feel that the use of 123I-MIBG scintigraphy
in patients with metastatic PGL should be limited to the
evaluation of whether the patient qualifies for 131I-MIBG
treatment.
FIG. 1. Continued.
TABLE 5. SDHB- vs. non-SDHB metastatic PGL
SDHB
(15 patients)
non-SDHB
(13 patients) P
18F-DOPAA 20% (25/126) 93% (79/85) 0.001
18F-FDAB 82% (103/126) 76% (65/85) 0.037
123I-MIBGC 57% (60/106) 59% (48/81) ns
18F-FDGD 83% (105/126) 62% (53/85) 0.001
Within SDHB patients: A vs. B, A vs. C, A vs. D, B vs. C, C vs. D: P 
0.01; B vs. D: P  ns. Within non-SDHB patients: A vs. B, A vs. C, A vs.
D: P  0.01; B vs. C: P  0.035; B vs. D, C vs. D: P  ns.
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Apart from its established role the localization of gas-
trointestinal carcinoid tumors (25–27), 18F-DOPA PET
has been suggested to be an excellent alternative for the
imaging of sympathetic (10, 28–30) and parasympathetic
(11, 31) PGL. In a study of 17 patients, 18F-DOPA PET
detected tumorswith a strikingly high sensitivity and spec-
ificity of both 100% (10). More recent studies confirmed
the usefulness of this technique in benign and malignant
abdominal PGL (29–32).We also show that 18F-DOPA is
a very useful alternative for the specific localization of
primaryPGL, although it canyieldboth false-negative and
false-positive results. In patients withmetastatic disease, a
per-lesion-based analysis showed a limited overall sensi-
tivity of 18F-DOPA PET: less than half of the metastases
detectedbyCT/MRIweredetectedby 18F-DOPAPET.On
the other hand, in 71% of patients with malignant PGL,
one or more metastases were discerned by the technique.
Moreover, a subgroup analysis indicated that its sensitiv-
ity is excellent for non-SDHBmetastases (94%) but poor
for SDHB-related metastases (20%). This discrepancy re-
mains unexplained. Our results are at variance with a pre-
viously published case series, in which 18F-DOPA PET
identified more metastases than MIBG single-photon
emission-computed tomography and 18F-FDG PET in
four of five patients with malignant PGL (31).
18F-FDA was initially developed at the National Insti-
tutes of Health for functional imaging of the sympathetic
nervous system and later evaluated as a new imaging tool
for PGL to optimally discern both primary tumors and
metastatic lesions. The present findings confirm the high
sensitivity of 18F-FDAPETpreviously shown for both pri-
mary tumors and metastases (13, 33) and show that 18F-
FDA PET/CT is superior to 18F-DOPA PET and 123I-
MIBG scintigraphy for localizing metastases. In fact, the
number of lesions detected by 18F-FDA PET far exceeded
thenumberof lesionsonCTandMRIandother functional
imaging modalities and were probably underestimated
due to truncation of lesion counts, whichwas necessary in
60%more regions for 18F-FDAPETthan forCTandMRI.
We found a surprisingly high sensitivity (88%) of 18F-
FDG PET for nonmetastatic PGL. Previously, sensitivities
ranging from58 to70%havebeen reported (6, 34).Wedo
not advocate the use of 18F-FDG for the first-line imaging
of PGL, because its uptake is not PGL-specific.
The observed differences in radiotracer accumulation
between primary tumors and metastases are likely related
to differences in tumor cell properties. Theoretically, ded-
ifferentiationmight lead to loss of the specific norepineph-
rine transporters in these tumors, but the avid accumula-
tion of 18F-FDA in the majority of metastatic lesions does
not support this theory. Alternatively, tracer accumulation
may be directly linked to genotype-specific tumor biology.
Malignant potential, tumor location, and biochemical phe-
notype are all closely linked to underlyingmutations in PGL
susceptibility genes (35, 36). In previous studiesweprovided
evidence for such a genetic signature on a tumor’s tracer
dynamics. For instance, we have shown that VHL PGLs
are better localized with 18F-FDA PET than 131I-MIBG
scintigraphy, which may be related to limited expres-
sion of norepinephrine transporters by VHL PGL cells
and a better affinity of 18F-FDA than MIBG for these
transporters (17, 37).
Our previous (8) and current observations in patients
with SDHB-related PGLprovide additional evidence for a
link between genotype-specific tumor biology and imag-
ing. SDHB mutations are associated with PGLs of a par-
ticularly high malignant potential (36). In the present
study, we confirm that 18F-FDGPET has an excellent sen-
sitivity for SDHB-associated metastatic PGL (8, 38). 18F-
FDG accumulation is an index of increased tissue glucose
metabolism, and, as a marker of tumor viability, the de-
gree of 18F-FDG uptake usually reflects tumor aggressive-
ness (22). In this study, the high sensitivity of 18F-FDG
PET was specific for SDHB-related metastases, rather
than a feature of PGL metastases in general. Therefore,
avid 18F-FDGuptake byPGLdoes not appear to bemerely
an indicatorof ahighmetabolic ratedue tomalignancyper
se but may rather be directly linked to SDHB-specific tu-
mor biology. The SDHB gene encodes for subunit B of the
mitochondrial succinate dehydrogenase complex II that
catalyzes the oxidation of succinate to fumarate in the
Krebs cycle and feeds electrons to the respiratory chain
ubiquinone pool, which ultimately leads to the generation
of ATP (oxidative phosphorylation). SDHB mutations
can lead to complete loss of succinate dehydrogenase en-
zymatic activity in malignant PGL, with up-regulation of
hypoxic-angiogenetic responsive genes (39). Impairment
of mitochondrial function due to loss of SDHB function
may cause tumor cells to shift from oxidative phosphor-
ylation to aerobic glycolysis, a phenomenon known as the
Warburg effect (40). Higher glucose requirement because
of a switch to less efficient pathways for cellular energy
productionmay explain the increased 18F-FDG uptake by
malignant SDHB-related PGL. This possible bioenerge-
netic signature on imaging awaits confirmation on a mo-
lecular level.
Based on our previous findings, we do not recommend
the use of 111In-pentetreotide scintigraphy as a first-line
imaging tool for PGL (8, 41). Novel somatostatin recep-
tor-based PET scanning using 68Ga-DOTA-peptides (42)
awaits further evaluation.
Our findings can assist practicing physicians in choos-
ing the most appropriate type of functional imaging for
individual patients with sympathetic, nonhead, and neck
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PGL. We recommend the use of 18F-FDA PET/CT in pa-
tients with a biochemically established diagnosis of PGL
when the aim is to localize the primary tumor(s) and rule
out metastases. If 18F-FDA PET/CT is unavailable, 18F-
DOPA PET/(CT) or 123I-MIBG scintigraphy can be used.
For patients with known metastatic PGL, we recommend
the use of 18F-FDA PET in patients with an unknown
genotype, 18F-FDG or 18F-FDA PET in SDHB mutation
carriers, and 18F-DOPA or 18F-FDA PET in non-SDHB
patients.
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